Corrugated surface microparticles with chitosan and levofloxacin for improved aerodynamic performance

• Published in: Asian journal of pharmceutical sciences Vol. 18; no. 3; p. 100815
• Main Authors: Han, Chang-Soo, Kang, Ji-Hyun, Park, Eun hye, Lee, Hyo-Jung, Jeong, So-Jeong, Kim, Dong-Wook, Park, Chun-Woong
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.05.2023; College of Pharmacy,Chungbuk National University,Cheongju 28160,Republic of Korea%College of Pharmacy,Chungbuk National University,Cheongju 28160,Republic of Korea; School of Pharmacy,Jeonbuk National University,Jeonju 54896,Republic of Korea%College of Pharmacy,Wonkwang University,Iksan 54538,Republic of Korea; Shenyang Pharmaceutical University; Elsevier
• Subjects: Aerodynamic performance; Chitosan; Corrugated surface; Levofloxacin; Organic acid; Original Research Paper; Levofloxacin; Aerodynamic performance; Chitosan; Corrugated surface; Organic acid
• ISSN: 1818-0876; 2221-285X
• DOI: 10.1016/j.ajps.2023.100815

Corrugated surface microparticles comprising levofloxacin (LEV), chitosan and organic acid were prepared using the 3-combo spray drying method. The amount and the boiling point of the organic acid affected the degree of roughness. In this study, we tried to improve the aerodynamic performance and increase aerosolization by corrugated surface microparticle for lung drug delivery efficiency as dry powder inhaler. HMP175 L20 prepared with 175 mmol propionic acid solution was corrugated more than HMF175 L20 prepared with 175 mmol formic acid solution. The ACI and PIV results showed a significant increase in aerodynamic performance of corrugated microparticles. The FPF value of HMP175 L20 was 41.3% ± 3.9% compared with 25.6% ± 7.7% of HMF175 L20. Corrugated microparticles also showed better aerosolization, decreased x-axial velocity, and variable angle. Rapid dissolution of drug formulations was observed in vivo. Low doses administered to the lungs achieved higher LEV concentrations in the lung fluid than high doses administered orally. Surface modification in the polymer-based formulation was achieved by controlling the evaporation rate and improving the inhalation efficiency of DPIs. [Display omitted]